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ACEI

:   angiotensin‐converting enzyme inhibitor

ARB

:   angiotensin receptor blocker

BNP

:   B‐type natriuretic peptide

CAD

:   coronary artery disease

EF

:   ejection fraction

HF

:   heart failure

HMDB

:   Human Metabolome Database

HR

:   hazard ratio

hsCRP

:   high‐sensitivity C‐reactive protein

hsTnI

:   high‐sensitivity troponin I

ICM

:   ischemic cardiomyopathy

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

*m/z*

:   mass‐to‐charge ratio

MS/MS

:   tandem mass spectrometry

N8AS

:   N8‐acetylspermidine

NICM

:   nonischemic cardiomyopathy

SAM

:   S‐adenosyl methionine

SAT 1/2

:   spermidine/spermine acetyltransferase 1/2

Clinical PerspectiveWhat Is New?N8‐Acetylspermidine (N8AS), a polyamine that is involved in the regulation of cardiomyocyte cell death and resultant cardiac dysfunction during ischemic injury, is a mechanistic biomarker that is upstream to the final‐common heart failure (HF) phenotype.Patients with ischemic cardiomyopathy (ICM) have higher N8AS levels than those with coronary artery disease without HF, or non‐ICM.Independent of traditional biomarkers, higher circulating N8AS levels are associated with higher mortality in patients with ICM in 2 independent cohorts and also with greater risk of incident HF in patients who have coronary artery disease without HF.What Are the Clinical Implications?A mechanistic biomarker that is upstream to the final HF phenotype may not only help refine prognostication but may also be a potential therapeutic target. In this context, N8AS is a novel mechanistic biomarker of ischemic cardiomyocyte death and resultant cardiac dysfunction.Independent of B‐type natriuretic peptide, high‐sensitivity troponin I, and high‐sensitivity C‐reactive protein, higher circulating N8AS is associated with higher mortality in patients with ICM and greater risk of incident HF in patients who have coronary artery disease without HF.Future studies should examine whether N8AS is a "modifiable" risk factor in ICM by examining the effect of modulation of polyamine levels by diet and pharmacological therapy on disease progression.

 {#jah35104-sec-0008}

While mortality associated with coronary artery disease (CAD) has declined over the past 2 decades, the incidence of heart failure (HF) attributable to CAD (ischemic cardiomyopathy \[ICM\]) has increased.[1](#jah35104-bib-0001){ref-type="ref"} ICM is the leading cause of HF with reduced ejection fraction (EF), accounting for approximately two thirds of all cases,[2](#jah35104-bib-0002){ref-type="ref"} and is associated with a worse prognosis compared with either CAD alone or with non‐ICM (NICM).[1](#jah35104-bib-0001){ref-type="ref"}

Several prognostic biomarkers associated with HF have been discovered. Most of these are reflective of either HF‐associated myocyte stretch (natriuretic peptides), myocardial injury or ischemia (high‐sensitivity troponin), or of the final‐common pathophysiology of progressive HF, regardless of the mechanism of HF development.[3](#jah35104-bib-0003){ref-type="ref"} In this context, a mechanistic biomarker that is upstream to the final HF phenotype may not only refine prognostication but also be a potential therapeutic target.[4](#jah35104-bib-0004){ref-type="ref"} Cardiac dysfunction in CAD is a complex process characterized by myocyte apoptosis and autophagy caused by both ischemia and ischemia/reperfusion injury.[5](#jah35104-bib-0005){ref-type="ref"} Polyamines, including spermidine and its derivatives, are aliphatic molecules that modulate the cardiac stress response to ischemia by regulating cardiomyocyte apoptosis[5](#jah35104-bib-0005){ref-type="ref"}, [6](#jah35104-bib-0006){ref-type="ref"} and autophagy.[7](#jah35104-bib-0007){ref-type="ref"}, [8](#jah35104-bib-0008){ref-type="ref"} Intracellular spermidine is catabolized by the enzyme spermidine N8‐acetyltransferase to N8‐acetylspermidine (N8AS).[9](#jah35104-bib-0009){ref-type="ref"}, [10](#jah35104-bib-0010){ref-type="ref"} N8AS is then excreted from the cell, and is therefore a plasma indicator of intracellular polyamine activity.[9](#jah35104-bib-0009){ref-type="ref"}, [10](#jah35104-bib-0010){ref-type="ref"} We have previously demonstrated reliable quantification of plasma N8AS concentrations using high‐resolution metabolomics profiling followed by reference standardization.[11](#jah35104-bib-0011){ref-type="ref"} Prior preclinical studies have established a key regulatory role for polyamines in cardiomyocyte cell death during the ischemic cascade,[5](#jah35104-bib-0005){ref-type="ref"}, [6](#jah35104-bib-0006){ref-type="ref"}, [7](#jah35104-bib-0007){ref-type="ref"}, [8](#jah35104-bib-0008){ref-type="ref"} as well as HF development. Pharmacological polyamine depletion has been shown to protect cardiomyocytes from ischemia‐induced apoptosis.[8](#jah35104-bib-0008){ref-type="ref"}, [12](#jah35104-bib-0012){ref-type="ref"}, [13](#jah35104-bib-0013){ref-type="ref"} However, there is a paucity of data on the translation of these findings to the use of polyamines as prognostic biomarkers in this population.[7](#jah35104-bib-0007){ref-type="ref"}

The purpose of our study was to investigate the association between plasma N8AS levels and progression of ICM. Our hypothesis was that: (1) N8AS levels will be higher in patients with ICM compared with those who have CAD without ICM and those with NICM; and (2) higher levels of N8AS, reflective of increased polyamine turnover and resultant cardiomyocyte death during ischemia will predict (a) adverse outcomes in ICM and (b) incident HF in those without HF. Prediction of adverse events was explored in a discovery cohort and replicated in an independent validation cohort. We further investigated whether the predictive capacity of N8AS was independent of BNP (B‐type natriuretic peptide), high‐sensitivity troponin I (hsTnI), and hsCRP (high‐sensitivity C‐reactive protein). Finally, using targeted and global metabolomics analyses, we investigated metabolic pathways that are associated with N8AS.

Methods {#jah35104-sec-0009}
=======

Study Population {#jah35104-sec-0010}
----------------

### Discovery Cohort {#jah35104-sec-0011}

We studied patients with CAD (defined as a history of myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, or an index left heart catheterization showing ≥50% stenosis in at least 1 major epicardial vessel) undergoing cardiac catheterization who were enrolled in the Emory Cardiovascular Biobank at 3 Emory Healthcare sites between 2003 and 2008.[14](#jah35104-bib-0014){ref-type="ref"} Participants were interviewed to collect information about demographic characteristics, medical history, and behavioral habits as previously described.[14](#jah35104-bib-0014){ref-type="ref"} CAD severity was evaluated using the modified Duke CAD Index with ≥50% stenosis classified as clinically significant. Echocardiographic left ventricular EF was abstracted after reviewing medical records. Medical records and *International Classification of Diseases, Ninth Revision* (*ICD*‐*9*) diagnostic codes were reviewed to confirm self‐reported medical history.

Patients who had HF with preserved EF (defined as a history of HF at enrollment *and* EF ≥50%) were excluded. Prevalent ICM was defined as the presence of physician diagnosis of HF or *ICD‐9* discharge diagnosis of HF *and* EF \<50%, or EF \<50% at the time of study enrollment.

### Validation Cohort {#jah35104-sec-0012}

Patients from the Atlanta Cardiomyopathy Consortium, a prospective cohort study that enrolled outpatients who had HF with reduced EF (EF \<50%) from 3 Emory University--affiliated hospitals in the greater metropolitan Atlanta area from 2007 to 2011, constituted the external validation cohort.[15](#jah35104-bib-0015){ref-type="ref"} Findings in the discovery cohort were validated in patients with ICM from this cohort. As a secondary analysis, we compared patients who had ICM with those who had NICM in the validation cohort.

All participants provided written informed consent at the time of enrollment, and both studies were approved by the institutional review board at Emory University, Atlanta, GA. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Follow‐Up and Outcomes {#jah35104-sec-0013}
----------------------

Study participants were prospectively followed for the primary outcome of all‐cause mortality and the secondary end point of HF hospitalization. Outcome censoring was performed on October 15, 2018. Follow‐up data were obtained by annual phone contact, electronic medical record review, data from the social security death index, and state records.[14](#jah35104-bib-0014){ref-type="ref"}, [15](#jah35104-bib-0015){ref-type="ref"} Incident HF was defined as the absence of a documented history of HF *and* EF \>50% at study enrollment, *and* HF hospitalization during follow‐up.

High‐Resolution Metabolomics for Metabolic Profiling {#jah35104-sec-0014}
----------------------------------------------------

High‐resolution metabolomics was performed using established methods.[11](#jah35104-bib-0011){ref-type="ref"}, [16](#jah35104-bib-0016){ref-type="ref"}, [17](#jah35104-bib-0017){ref-type="ref"} All patients underwent an overnight fast before blood collection. Plasma specimens were collected before catheterization and stored at −80°C. Samples were extracted and analyzed as previously described.[11](#jah35104-bib-0011){ref-type="ref"}, [17](#jah35104-bib-0017){ref-type="ref"} Briefly, extractions were performed with acetonitrile containing a mixture of internal standards and maintained in an autosampler at 4°C until injection. Each sample was analyzed using a Thermo LTQ Velos Orbitrap high‐resolution (60 000 mass resolution) mass spectrometer (Thermo Fisher Scientific) and C18 column chromatography.[11](#jah35104-bib-0011){ref-type="ref"}, [17](#jah35104-bib-0017){ref-type="ref"} For the validation cohort, samples were analyzed using liquid chromatography--Fourier transform mass spectrometry (Accela‐LTQ Velos Orbitrap; mass‐to‐charge ratio \[*m/z*\] range from 85 to 850 ppm) with 10‐uL injection volume using a dual chromatography setup (anion exchange and HILIC C18) and a formic acid/acetonitrile gradient. Electrospray ionization was used in the positive ion mode. Data were extracted using apLCMS[18](#jah35104-bib-0018){ref-type="ref"} with modifications by xMSanalyzer as *m/z* features,[16](#jah35104-bib-0016){ref-type="ref"} where an *m/z* feature is defined by *m/z*, retention time, and ion intensity (integrated ion intensity for the chromatographic peak). Metabolite annotation was performed using xMSannotator v1.3.2 using Human Metabolome Database (HMDB) v3.6.[19](#jah35104-bib-0019){ref-type="ref"} Identity of N8AS was previously confirmed via tandem mass spectrometry (MS/MS) and matching fragmentation pattern and retention time with the authentic standard.[11](#jah35104-bib-0011){ref-type="ref"}

Quantification of N8AS {#jah35104-sec-0015}
----------------------

In the discovery cohort, quantification of N8AS was accomplished using a reference standardization protocol using NIST SRM 1950 and a pooled reference plasma analyzed with each batch ("Q standard") as previously described.[11](#jah35104-bib-0011){ref-type="ref"} Based on triplicate analysis of the Q standard, the concentration of N8AS within the Q standard was determined to be 5.62±1.92 nmol/L. In the validation cohort, N8AS was reported as feature intensities.

Biomarker Measurements {#jah35104-sec-0016}
----------------------

Levels of BNP (ARCHITECT BNP chemiluminescent microparticle immunoassay, Abbott Laboratories, reported in pg/mL), hsTnI (ARCHITECT STAT High Sensitive Troponin‐I chemiluminescent microparticle immunoassay, Abbott Laboratories, reported in pg/mL), and hsCRP (MULTIGENT CRP Vario latex immunoassay, Abbott Laboratories, reported in mg/L) were measured as previously described.[20](#jah35104-bib-0020){ref-type="ref"}, [21](#jah35104-bib-0021){ref-type="ref"}

Metabolome‐Wide Association Study of N8AS {#jah35104-sec-0017}
-----------------------------------------

All metabolite features were measured in triplicates, and median intensities were taken from the nonzero readings. Features with \>20% zero readings were excluded. Metabolome‐wide association study of N8AS was then performed using Spearman rank--based correlation to determine metabolites that significantly correlated with N8AS using false discovery rate \<0.01 (Benjamini and Hochberg method, denominator: 5719 detectable features).[22](#jah35104-bib-0022){ref-type="ref"} These metabolites were selected for pathway enrichment analysis in Mummichog (version 2.0.6).[23](#jah35104-bib-0023){ref-type="ref"} Identities of many of the *m/z* features are known from previous research using ion dissociation patterns by MS/MS, coelution with authentic standards, and cross‐platform validation.[11](#jah35104-bib-0011){ref-type="ref"}, [17](#jah35104-bib-0017){ref-type="ref"}, [19](#jah35104-bib-0019){ref-type="ref"} Possible identities of other *m/z* features were obtained using the METLIN Mass Spectrometry Database,[24](#jah35104-bib-0024){ref-type="ref"} HMDB[25](#jah35104-bib-0025){ref-type="ref"} and Kyoto Encyclopedia of Genes and Genomes (KEGG).[26](#jah35104-bib-0026){ref-type="ref"} Metabolite identification levels[27](#jah35104-bib-0027){ref-type="ref"} were assigned by comparison with the in‐house library of confirmed metabolites, which includes metabolites confirmed using MS/MS and retention time with authentic standards (level 1), comparison of MS/MS with experimental spectra in online databases or in silico predicted spectra (level 2), annotation at the metabolite class level (level 3), medium or high confidence databases matches from xMSannotator (level 4), and accurate mass match (level 5).

### Targeted Network and Pathway Analysis {#jah35104-sec-0018}

KEGG[26](#jah35104-bib-0026){ref-type="ref"} Mapper was used to target polyamine metabolism. Matches to adducts for metabolites in pathways associated with polyamine metabolism were selected using HMDB[25](#jah35104-bib-0025){ref-type="ref"} and KEGG.[26](#jah35104-bib-0026){ref-type="ref"} Correlation of metabolites with N8AS was determined as previously described.

Statistical Analysis {#jah35104-sec-0019}
--------------------

Data are presented as mean±SD, median (interquartile range), or number (percentage) of patients. Baseline characteristics were compared between groups using Student *t* test or ANOVA for normally distributed continuous variables, Mann--Whitney *U* tor Kruskal--Wallis test for non‐normally distributed continuous variables, and chi‐square test for categorical variables.

N8AS levels were log~2~‐transformed and standardized (expressed per 1 SD; *z* score) for all analyses. Cox proportional hazards models were used to determine the association of N8AS with outcomes, adjusted for age, sex, race, creatinine, body mass index, smoking history, diagnosis of diabetes mellitus, hypertension, and hyperlipidemia; with and without inclusion of other biomarkers (BNP, hsTnI, and hsCRP) in the models. We used Schoenfeld residuals to check the proportional hazards assumption and found no evidence of violation. Less than 10% of patients had missing biomarker data, and available case analysis was performed. *P*\<0.05 was considered statistically significant.

Data were analyzed using SAS statistical software version 9.4 (SAS Institute Inc) and R statistical software (version 3.5.1, R Foundation for Statistical Computing).

Results {#jah35104-sec-0020}
=======

Baseline Characteristics: Discovery Cohort {#jah35104-sec-0021}
------------------------------------------

The discovery cohort consisted of 474 patients with CAD (mean age: 67.7±11.0 years; 25.9% women, 11.8% black), 320 without ICM, and 154 with ICM (Table [1](#jah35104-tbl-0001){ref-type="table"}). Risk factor profile was similar in those with and without ICM, but levels of BNP, hsTnI, and hsCRP were higher in patients with ICM. Patients with ICM had higher levels of N8AS than those without ICM (ICM: 10.39 \[7.21--17.75\] nmol/L; no ICM: 8.29 \[5.91--11.42\] nmol/L \[*P*\<0.001\]). There was a similar variation in log~2~‐transformed, standardized N8AS levels (ICM: 0.23±0.56; no ICM: −0.11±1.14 \[*P*\<0.001\]). A modest correlation was observed between N8AS levels and BNP (*r*=0.40, *P*\<0.001) and hsCRP (*r*=0.26, *P*\<0.001), but not with hsTnI levels (*r*=0.07, *P*=0.14).

###### 

Baseline Characteristics of Participants in the Discovery Cohort

                                                                   CAD/No ICM (n=320)        Prevalent ICM (n=154)       *P* Value
  ---------------------------------------------------------------- ------------------------- --------------------------- -----------
  Demographic data                                                                                                       
  Age, y                                                           67.44±10.77               68.32±10.50                 0.40
  Male sex                                                         234 (73.1)                117 (76.0)                  0.51
  Black race                                                       35 (10.9)                 21 (13.6)                   0.39
  Clinical data                                                                                                          
  Diabetes mellitus                                                124 (38.8)                72 (46.8)                   0.10
  Hypertension                                                     230 (71.9)                105 (68.2)                  0.41
  Hyperlipidemia                                                   225 (70.3)                100 (64.9)                  0.24
  Smoking history                                                  216 (67.5)                107 (69.5)                  0.67
  Body mass index, kg/m^2^                                         28.78±5.08                28.24±4.82                  0.27
  Serum creatinine, mg/dL                                          1.30±1.27                 1.35±0.68                   0.60
  Ejection fraction, %                                             56.31±6.24                30.31±9.92                  \<0.001
  Modified Duke CAD Index[a](#jah35104-note-0004){ref-type="fn"}   53.07±26.35               57.15±28.24                 0.16
  Medication history                                                                                                     
  ACEI/ARB                                                         215 (67.2)                116 (75.3)                  0.07
  β‐Blocker                                                        245 (76.6)                125 (81.2)                  0.26
  Biomarkers                                                                                                             
  BNP, pg/mL                                                       98.10 \[47.08--206.78\]   325.40 \[125.60--739.38\]   \<0.001
  hsTnI, pg/mL                                                     6.90 \[3.60--17.60\]      20.75 \[9.10--72.98\]       \<0.001
  hsCRP, mg/L                                                      3.10 \[1.20--7.45\]       5.35 \[2.03--10.00\]        0.001

Data are expressed as mean±SD, median \[interquartile range\], or number (percentage). ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, B‐type natriuretic peptide; CAD, coronary artery disease; hsCRP, high‐sensitivity C‐reactive protein; hsTnI, high‐sensitivity troponin I; and ICM, ischemic cardiomyopathy.

Data missing for 15.2% of patients.

Elevated N8AS levels (per 1‐SD increase in log~2~‐transformed, standardized N8AS) were independently associated with higher risk of ICM (adjusted odds ratio, 2.97; 95% CI, 1.94--4.54 \[*P*\<0.001\]).

N8AS Levels and Cardiovascular Outcomes in ICM: Discovery Cohort {#jah35104-sec-0022}
----------------------------------------------------------------

During a median follow‐up of 3.4 (interquartile range, 1.6--6.3) years, there were 109 (70.1%) all‐cause death events and 62 (40.2%) HF hospitalizations in patients with ICM. Elevated N8AS levels (per 1‐SD increase in log~2~‐transformed, standardized N8AS) were independently associated with greater mortality (adjusted hazard ratio \[HR\], 1.48; 95% CI, 1.19--1.85 \[*P*=0.001\]) and higher risk for HF hospitalization (adjusted HR, 1.72; 95% CI, 1.27--2.33 \[*P*\<0.001\]), independent of BNP, hsTnI, and hsCRP (Table [2](#jah35104-tbl-0002){ref-type="table"}, Figure [1](#jah35104-fig-0001){ref-type="fig"}).

###### 

HR Estimates for the Association Between N8AS Levels (Log~2~‐Transformed, Standardized), All‐Cause Mortality, and HF Hospitalizations in Patients With ICM

  Discovery Cohort                                         All‐Cause Mortality[a](#jah35104-note-0006){ref-type="fn"}   HF Hospitalization[a](#jah35104-note-0006){ref-type="fn"}                       
  -------------------------------------------------------- ------------------------------------------------------------ ----------------------------------------------------------- ------------------- ---------
  Unadjusted (n=154)                                       1.54 (1.26--1.87)                                            \<0.001                                                     1.54 (1.19--2.01)   0.001
  Model 1 (n=154)[b](#jah35104-note-0007){ref-type="fn"}   1.48 (1.19--1.85)                                            0.001                                                       1.72 (1.27--2.33)   \<0.001
  Model 1+BNP (n=144)                                      1.39 (1.11--1.75)                                            0.005                                                       1.62 (1.17--2.24)   0.004
  Model 1+hsTnI (n=152)                                    1.45 (1.16--1.81)                                            0.001                                                       1.71 (1.26--2.32)   0.001
  Model 1+hsCRP (n=152)                                    1.43 (1.14--1.79)                                            0.002                                                       1.66 (1.22--2.25)   0.001
  Model 1+BNP+hsTnI+hsCRP (n=142)                          1.34 (1.06--1.69)                                            0.01                                                        1.56 (1.13--2.16)   0.008

BNP indicates B‐type natriuretic peptide (in pg/mL); HF, heart failure; hsCRP, high‐sensitivity C‐reactive protein (in mg/L); hsTnI, high‐sensitivity troponin I (in pg/mL); ICM, ischemic cardiomyopathy; and N8AS, N8‐acetylspermidine.

Hazard ratios (HRs) were calculated with the use of Cox regression models incorporating covariates listed in the table.

Model 1 adjusted for age, sex, race, creatinine, presence of diabetes mellitus, hypertension, hyperlipidemia, body mass index, and smoking history.

![Kaplan--Meier curves for outcomes stratified by N8‐acetylspermidine (N8AS) tertiles.\
**A**, All‐cause mortality by N8AS tertiles, and (**B**) heart failure hospitalization--free survival by N8AS tertiles.](JAH3-9-e016055-g001){#jah35104-fig-0001}

Incremental Prognostic Value to BNP {#jah35104-sec-0023}
-----------------------------------

In a multivariate model including all aforementioned covariates, together with BNP and N8AS, both were independent predictors of events. When stratified by BNP (high BNP: \>100 pg/mL) and N8AS (high N8AS: \>median) levels, patients with high levels of both biomarkers had the highest risk, patients with low levels of both biomarkers had the lowest risk, and patients with elevation of only 1 biomarker had intermediate risk of all‐cause mortality and HF hospitalizations ([Table S1](#jah35104-sup-0001){ref-type="supplementary-material"}, Figure [2](#jah35104-fig-0002){ref-type="fig"}).

![Kaplan--Meier curves for outcomes by BNP (B‐type natriuretic peptide)--N8‐acetylspermidine (N8AS) strata (high BNP: \>100 pg/mL, high N8AS: \>median).\
**A**, All‐cause mortality by BNP‐N8AS strata, and (**B**) heart failure (HF) hospitalization--free survival BNP‐N8AS strata.](JAH3-9-e016055-g002){#jah35104-fig-0002}

N8AS Levels and Cardiovascular Outcomes in ICM: Validation Cohort {#jah35104-sec-0024}
-----------------------------------------------------------------

The external validation cohort consisted of 85 patients with ICM (mean age: 60.3±11.6 years; 18.8% women, 36.5% black) ([Table S2](#jah35104-sup-0001){ref-type="supplementary-material"}). Patients in the validation cohort were younger, more likely to be black and receive β‐blockers, less likely to smoke, and had a lower left ventricular EF than patients with ICM in the discovery cohort. All other baseline characteristics were comparable.

During a median follow‐up of 6.2 years (interquartile range, 3.3--9.3 years), there were 34 (40.0%) all‐cause deaths. Similar to the discovery cohort, elevated N8AS levels (per 1‐SD increase in log~2~‐transformed, standardized N8AS) were associated with higher mortality in the validation cohort (adjusted HR, 1.97; 95% CI, 1.08--3.60 \[*P*=0.03\]). The association between N8AS and mortality was independent of BNP levels (adjusted HR, 2.30; 95% CI, 1.19--4.44 \[*P*=0.01\]).

N8AS Levels and Incident HF {#jah35104-sec-0025}
---------------------------

Of the discovery cohort of patients with CAD without HF at the time of enrollment (n=320), 22 (6.9%) developed incident HF during a median follow‐up of 6.1 years (interquartile range, 2.8--9.3 years). Patients with incident HF had a similar risk factor profile compared with those who did not, but levels of BNP were higher in patients who developed incident HF ([Table S3](#jah35104-sup-0001){ref-type="supplementary-material"}). Elevated N8AS levels (per 1‐SD increase in log~2~‐transformed, standardized N8AS) were independently associated with higher risk of incident HF (adjusted HR, 4.16; 95% CI, 1.41--12.25 \[*P*=0.01\]), independent of BNP, hsTnI, and hsCRP (Table [3](#jah35104-tbl-0003){ref-type="table"}).

###### 

HR Estimates for the Association Between N8AS Levels (Log~2~‐Transformed, Standardized) and Incident HF in Patients Who Had CAD Without HF at Baseline

  Discovery Cohort                                         Incident HF[a](#jah35104-note-0009){ref-type="fn"}   
  -------------------------------------------------------- ---------------------------------------------------- -------
  Unadjusted (n=320)                                       5.19 (1.83--14.74)                                   0.002
  Model 1 (n=320)[b](#jah35104-note-0010){ref-type="fn"}   4.16 (1.41--12.25)                                   0.01
  Model 1+BNP (n=293)                                      4.35 (1.46--12.96)                                   0.008
  Model 1+hsTnI (n=316)                                    3.94 (1.33--11.68)                                   0.01
  Model 1+hsCRP (n=306)                                    4.14 (1.39--12.36)                                   0.01
  Model 1+BNP+hsTnI+hsCRP (n=284)                          4.14 (1.35--12.69)                                   0.01

BNP indicates B‐type natriuretic peptide (in pg/mL); CAD, coronary arterydisease; HF, heart failure; hsCRP, high‐sensitivity C‐reactive protein (in mg/L); hsTnI, high‐sensitivity troponin I (in pg/mL); and N8AS, N8‐acetylspermidine.

Hazard ratios (HRs) were calculated with the use of Cox regression models incorporating covariates listed in the table.

Model 1 adjusted for age, sex, race, creatinine, presence of diabetes mellitus, hypertension, hyperlipidemia, body mass index, and smoking history.

N8AS Levels and NICM {#jah35104-sec-0026}
--------------------

To explore the effect of Etiology on N8AS levels, we performed a secondary analysis comparing patients who had NICM (n=131) with those who had ICM (n=85) in the validation cohort. Patients with ICM had higher N8AS (log~2~‐transformed, standardized) levels (ICM: 0.18±0.81; NICM: −0.12±1.09 \[*P*=0.02\]) but similar levels of BNP (*P*=0.10) ([Table S4](#jah35104-sup-0001){ref-type="supplementary-material"}). There was a significant Etiology\*N8AS interaction in the prediction of all‐cause mortality (*P*=0.02, ratio of HR in ICM:NICM per 1‐SD increase in log~2~‐transformed, standardized N8AS: 1.97). Unlike in ICM, N8AS levels (per 1‐SD increase in log~2~‐transformed, standardized N8AS) were not significantly associated with mortality in the NICM cohort (adjusted HR, 1.06; 95% CI, 0.77--1.46 \[*P*=0.72\]).

Metabolic Pathways Associated With N8AS {#jah35104-sec-0027}
---------------------------------------

A total of 5719 detected features in the 474 patients in the discovery cohort entered global metabolomics analysis to determine metabolic pathways associated with N8AS. At a false discovery rate q threshold \<0.01, there were 203 features that correlated with N8AS ([Table S5](#jah35104-sup-0001){ref-type="supplementary-material"}). Pathway enrichment analysis demonstrated that these features mapped to 2 metabolic pathways: the carnitine shuttle (*P*=0.007) and the saturated fatty acids β‐oxidation pathway (*P*=0.04) (Table [4](#jah35104-tbl-0004){ref-type="table"}).

###### 

Metabolites From Global and Targeted Network and Pathway Analysis That Significantly Correlated With N8AS

  Name                                                                                                   *m/z*\_Retention Time, s   Spearman Correlation Coefficient   *P* Value   False Discovery Rate Q Value   HMDB (Identification Level\*)               Adduct
  ------------------------------------------------------------------------------------------------------ -------------------------- ---------------------------------- ----------- ------------------------------ ------------------------------------------- --------
  Global metabolic pathway and network analysis                                                                                                                                                                                                               
  Carnitine shuttle                                                                                                                                                                                                                                           
  α‐Linolenyl carnitine                                                                                  mz422.3266_t368            0.17                               1.53E‐04    5.83E‐03                       HMDB06319 (level 4)                         M+H
  Tetradecanoyl carnitine                                                                                mz372.3102_t366            0.22                               1.09E‐06    1.45E‐04                       HMDB05066 (level 2)                         M+H
  L‐palmitoylcarnitin                                                                                    mz400.3414_t398            0.16                               3.54E‐04    9.92E‐03                       HMDB00222 (level 1)                         M+H
  Trans‐hexadec‐2enoyl carnitin                                                                          mz398.3258_t376            0.20                               7.18E‐06    6.62E‐04                       HMDB06317 (level 4)                         M+H
  Linoelaidyl carnitine                                                                                  mz424.3414_t384            0.20                               8.17E‐06    7.05E‐04                       HMDB06461 (level 4)                         M+H
  Timnodonyl carnitine                                                                                   mz468.3082_t411            −0.17                              1.72E‐04    6.29E‐03                       NA (level 4)                                M+Na
  Saturated fatty acids β oxidation                                                                                                                                                                                                                           
  L‐palmitoylcarnitine                                                                                   mz400.3414_t398            0.16                               3.54E‐04    9.92E‐03                       HMDB00222 (level 1)                         M+H
  Targeted metabolic pathway and network analysis                                                                                                                                                                                                             
  Polyamine metabolism                                                                                                                                                                                                                                        
  Isoputreanine                                                                                          mz161.129_t38              0.17                               1.39E‐04    5.55E‐03                       HMDB06009 (level 4)                         M+H
  Methionine/cysteine metabolism                                                                                                                                                                                                                              
  L‐methionine                                                                                           mz172.0403_t39             0.21                               2.47E‐06    2.83E‐04                       HMDB00696 (level 4)                         M+Na
  Cystathionine ketimine                                                                                 mz204.0328_t142            0.14                               1.89E‐03    0.03                           HMDB02015 (level 4)                         M+H
  Cystathionine sulfoxide                                                                                mz239.0712_t32             0.11                               0.02        0.12                           HMDB02399 (level 4)                         M+H
  N‐ornithyl‐L‐taurine                                                                                   mz240.0994_t438            −0.13                              3.55E‐03    0.04                           HMDB33519 (level 4)                         M+H
  4‐Hydroxy‐17β‐estradiol‐2‐S‐glutathione                                                                mz594.249_t421             −0.17                              2.26E‐04    7.58E‐03                       HMDB60139 (level 4)                         M+H
  Serine                                                                                                 mz106.0495_t42             0.11                               0.01        0.09                           HMDB00187; HMDB03406 (level 1)              M+H
  Cysteinyl‐cysteine                                                                                     mz225.0347_t38             0.10                               0.03        0.15                           HMDB28772 (level 4)                         M+H
  Methylmalonate                                                                                         mz141.0145_t33             0.11                               0.01        0.10                           HMDB00202 (level 4)                         M+Na
  γ‐L‐glutamyl‐L‐cysteine                                                                                mz251.0701_t374            0.15                               1.07E‐03    0.02                           HMDB01049 (level 4)                         M+H
  Urea cycle metabolism                                                                                                                                                                                                                                       
  Argininosuccinic acid; N2‐(3‐hydroxysuccinoyl)arginine; N2‐(3‐carboxy‐2‐hydroxy‐1‐oxopropyl)arginine   mz291.13_t416              −0.11                              0.01        0.10                           HMDB00052; HMDB32765; HMDB39408 (level 4)   M+H
  Hippurate                                                                                              mz180.0656_t68             0.19                               4.55E‐05    2.52E‐03                       HMDB00714 (level 2)                         M+H
  4‐Acetamidobutanoate                                                                                   mz146.081_t47              −0.12                              8.93E‐03    0.07                           HMDB03681 (level 2)                         M+H
  Peptide 2‐\[3‐carboxy‐3‐(methylammonio)propyl\]‐L‐histidine                                            mz294.13_t420              −0.12                              8.76E‐03    0.07                           NA                                          M+Na
  Asparagine                                                                                             mz133.0603_t47             −0.12                              9.54E‐03    0.07                           HMDB00168 (level 1)                         M+H
  Asymmetric dimethylarginine; symmetric dimethylarginine                                                mz203.1503_t37             −0.10                              0.03        0.15                           HMDB01539; HMDB03334 (level 4)              M+H

M+Na indicates sodium adduct; *m/z*, mass‐to‐charge ratio; NA, not annotated in Human Metabolome Database (HMDB); and N8AS, N8‐acetylspermidine.

1Metabolite identification levels are adapted from the criteria proposed by Schymanski et al: Level 1 confirmed by tandem mass spectrometry (MS/MS) and co‐elution with authentic standards;Level 2 confirmed by MS/MS and matches with online databases or in silico predicted spectraLevel 3 confirmed by MS/MS at the chemical class level, but no evidence for a specific metaboliteLevel 4 computationally assigned annotation using xMSannotator (medium or high confidence)Level 5 accurate mass match2For metabolites with multiple adduct matches, only the hydrogen adduct (M+H) adduct is reported here.

Targeted correlation analysis of metabolites in 3 central pathways of N8AS‐associated metabolism (polyamine metabolism, methionine metabolism, and urea cycle) (Figure [3](#jah35104-fig-0003){ref-type="fig"}) revealed 16 significant correlations at a false discovery rate q\<0.2 (Table [4](#jah35104-tbl-0004){ref-type="table"}). Most urea cycle metabolites were negatively correlated, while those involved in methionine metabolism were positively correlated with N8AS.

![Correlated metabolites by targeted network and pathway analysis of N8‐acetylspermidine (N8AS)‐related pathways.\
In red: Negatively correlated with N8AS. In blue: Positively correlated with N8AS. SAM indicates S‐adenosyl methionine; and SAT 1/2, spermidine/spermine acetyltransferase 1/2.](JAH3-9-e016055-g003){#jah35104-fig-0003}

Discussion {#jah35104-sec-0028}
==========

The major findings of this study are: (1) N8AS levels are higher in patients with ICM compared with patients who have CAD without ICM and NICM; (2) higher circulating N8AS levels are associated with higher mortality in patients with ICM, independent of BNP; and (3) higher N8AS levels in patients who have CAD without HF are associated with greater risk of incident HF (Figure [4](#jah35104-fig-0004){ref-type="fig"}). N8AS levels correlate with metabolites in the carnitine shuttle and the saturated fatty acid β‐oxidation pathway, as well as known pathways of N8AS‐associated metabolism.

![Summary of study findings.\
N8‐Acetylspermidine (N8AS) levels are higher in patients with ischemic cardiomyopathy (ICM) compared with patients who had coronary artery disease (CAD) without ICM (*P*\<0.001) and non‐ICM (NICM) (*P*=0.02). Higher circulating N8AS levels are associated with higher mortality in patients with ICM but not in patients with NICM. Higher N8AS levels in patients who have CAD without heart failure (HF) are associated with greater risk of incident HF. N8AS levels are log~2~‐transformed and standardized (expressed per 1 SD). All analyses were adjusted for age, sex, race, creatinine, presence of diabetes mellitus, hypertension, hyperlipidemia, body mass index, and smoking history.](JAH3-9-e016055-g004){#jah35104-fig-0004}

HF with reduced EF affects over 2.5 million Americans, with \>50% mortality within 5 years of diagnosis.[28](#jah35104-bib-0028){ref-type="ref"} The incorporation of natriuretic peptides into clinical practice has refined prognostication in patients with HF; however, the residual risk of adverse outcomes remains high.[3](#jah35104-bib-0003){ref-type="ref"} Consequently, with the technological evolution of high‐throughput ‐omics platforms over the past decade, there has been a surge in the identification of new biomarkers reflective of the final‐common pathophysiology of progressive HF[29](#jah35104-bib-0029){ref-type="ref"}: inflammation (CRP), extracellular‐matrix remodeling (galectin‐3), myocyte injury (troponins I and T), and myocyte stress (BNP, soluble ST2, growth differentiation factor 15).[3](#jah35104-bib-0003){ref-type="ref"} However, a biomarker upstream to the final‐common pathway for HF, and specific to the mechanism of HF development, would likely provide additional prognostic value.[4](#jah35104-bib-0004){ref-type="ref"} Ischemic HF is a result of cardiomyocyte damage from calcium overload, oxidative stress, and activation of cellular apoptosis and autophagy occurring both during ischemia and reperfusion injury,[30](#jah35104-bib-0030){ref-type="ref"} mechanisms unique to an ischemic pathogenesis for HF.[31](#jah35104-bib-0031){ref-type="ref"} Moreover, since no currently available therapies successfully target ischemia/reperfusion injury, which accounts for nearly 50% of the total ischemic damage to the heart,[32](#jah35104-bib-0032){ref-type="ref"} a biomarker specific to the ischemic cascade may also elucidate novel therapeutic targets.

Polyamines, including spermidine, spermine, and their derivatives, including N8AS, are ubiquitous aliphatic molecules with a well‐recognized role in cardiac cell growth, differentiation, and protein synthesis.[13](#jah35104-bib-0013){ref-type="ref"} Specifically, they are key mediators of the ischemic cascade,[33](#jah35104-bib-0033){ref-type="ref"} by regulating apoptosis or programmed cell death,[5](#jah35104-bib-0005){ref-type="ref"}, [6](#jah35104-bib-0006){ref-type="ref"} and autophagy,[34](#jah35104-bib-0034){ref-type="ref"} the principal cellular mechanisms for ischemia and reperfusion injury and subsequent cardiac failure.[35](#jah35104-bib-0035){ref-type="ref"}, [36](#jah35104-bib-0036){ref-type="ref"} In preclinical studies, acute ischemia activates the myocardial polyamine stress response, resulting in polyamine accumulation and consequent cardiomyocyte death.[8](#jah35104-bib-0008){ref-type="ref"}, [37](#jah35104-bib-0037){ref-type="ref"} On the other hand, polyamine degradation via acetylation is enhanced during ischemia/reperfusion injury,[37](#jah35104-bib-0037){ref-type="ref"} a reaction that also mediates ischemic apoptosis and autophagy caused by the generation of toxic metabolic products and oxidative stress.[33](#jah35104-bib-0033){ref-type="ref"} Additionally, polyamines regulate nitric oxide/cGMP pathway--mediated signaling[38](#jah35104-bib-0038){ref-type="ref"} and calcium homeostasis[39](#jah35104-bib-0039){ref-type="ref"} during ischemia/reperfusion injury. Inhibition of the rate‐limiting enzyme of polyamine biosynthesis: ornithine decarboxylase, by α‐difluoromethylornithine protects cardiomyocytes from ischemia‐induced apoptosis via polyamine depletion.[8](#jah35104-bib-0008){ref-type="ref"}, [12](#jah35104-bib-0012){ref-type="ref"}, [13](#jah35104-bib-0013){ref-type="ref"} In this study, we show that higher levels of plasma N8AS, an excretory product of intracellular spermidine that is reflective of increased polyamine turnover,[9](#jah35104-bib-0009){ref-type="ref"}, [10](#jah35104-bib-0010){ref-type="ref"} is reproducibly associated with worse clinical outcomes in 2 independent cohorts with ICM. Moreover, we confirmed the associations between N8AS and other known polyamine‐associated pathway metabolites (Figure [4](#jah35104-fig-0004){ref-type="fig"}). Interestingly, while the regulation of cardiomyocyte death is the principal pathophysiological role for polyamines during the ischemic cascade,[5](#jah35104-bib-0005){ref-type="ref"}, [6](#jah35104-bib-0006){ref-type="ref"}, [34](#jah35104-bib-0034){ref-type="ref"} we did not find a correlation between N8AS and hsTnI levels in our study. However, troponin is also released from intact cells by cleavage and membrane permeability during increased cardiac metabolic demand, potentially explaining our findings.

Other clinical studies have also helped to elucidate the role of polyamines in the pathogenesis of cardiovascular disease. In a prospective analysis of 658 patients from the Bruneck study,[7](#jah35104-bib-0007){ref-type="ref"} higher dietary intake of spermidine, assessed by food questionnaires, was associated with a decreased risk of HF, as well as a composite outcome of acute coronary syndrome, stroke, and death from vascular disease.[7](#jah35104-bib-0007){ref-type="ref"} In an exploratory analysis, the authors showed inverse associations between spermidine intake and chitinase‐3‐like protein 1, implicated in atherosclerotic plaque inflammation and rupture, and with growth differentiation factor 15 levels, a known marker of HF progression.[7](#jah35104-bib-0007){ref-type="ref"} Two previous metabolomics studies found that higher spermidine was part of a metabolite panel that predicted the presence of HF, as well as adverse outcomes in HF, independent of BNP and galectin‐3.[40](#jah35104-bib-0040){ref-type="ref"}, [41](#jah35104-bib-0041){ref-type="ref"} However, since spermidine was part of a panel that also included essential amino acids, butyrylcarnitine and dimethylarginine/arginine ratio, the relative contribution of spermidine to the risk profile was not clearly elucidated. Additionally, these studies did not explore the effect of HF etiology on prognostication. We have shown that N8AS predicts outcomes in the ICM but not in the NICM population. Another novel finding of our study is that higher N8AS levels predict incident HF in patients with CAD. There is a paucity of data on the use of polyamines as biomarkers for incident HF prediction. Whether increased N8AS levels reflect a decrease in intracellular spermidine bioavailability, or increased spermidine production and degradation in response to ischemic stress, requires further exploration.

Study Strengths and Limitations {#jah35104-sec-0029}
===============================

The major strengths of our study include the robust confirmation and quantification of N8AS levels, as well as the validation of our findings in an independent validation cohort that utilized different mass spectrometry and chromatography techniques, overcoming concerns regarding reproducibility of metabolomics studies. Limitations include the small validation cohort sample size and a lack of serial N8AS measurements. This precluded estimations of N8AS variability with acute decompensated HF.

Conclusions {#jah35104-sec-0030}
===========

Circulating N8AS levels are higher in patients with ICM compared with those who have CAD without ICM and NICM. Higher levels are predictive of mortality and HF hospitalizations in patients with ICM, and with incident HF in those without HF, independent of BNP, hsTnI, and CRP levels. Whether N8AS is a risk factor for ICM and whether the modulation of polyamine metabolism and levels via diet[32](#jah35104-bib-0032){ref-type="ref"} and pharmacological therapy, such as α‐difluoromethylornithine,[8](#jah35104-bib-0008){ref-type="ref"}, [12](#jah35104-bib-0012){ref-type="ref"}, [13](#jah35104-bib-0013){ref-type="ref"} affect disease progression needs further investigation.

Sources of Funding {#jah35104-sec-0031}
==================

Mehta is supported by American Heart Association grant 19POST34400057 and the Abraham J. & Phyllis Katz Foundation. Dhindsa is supported by the Abraham J. & Phyllis Katz Foundation. Morris is supported by funding from National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute K23 HL124287 and the Robert Wood Johnson Foundation (Harold Amos Medical Faculty Development Program). Quyyumi is supported by NIH grants 1P20HL113451‐01, 1R61HL138657‐02, 1P30DK111024‐03S1, 5R01HL095479‐08, 3RF1AG051633‐01S2, 5R01AG042127‐06, 2P01HL086773‐08, U54AG062334‐01, 1R01HL141205‐01, 5P01HL101398‐02, 1P20HL113451‐01, 5P01HL086773‐09, 1RF1AG051633‐01, R01 NS064162‐01, R01 HL89650‐01, HL095479‐01, 1DP3DK094346‐01, and 2P01HL086773, and American Heart Association grant 15SFCRN23910003.

Disclosures {#jah35104-sec-0032}
===========

None.

Supporting information
======================

###### 

**Tables S1--S5**

###### 

Click here for additional data file.
